By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



5 Centerpointe Drive
Suite 400
Lake Oswego  Oregon  97035  U.S.A.
Phone: 971-204-0382 Fax: n/a



Company News
CytoDyn Release: HIV Patients Successfully Reach One Year Of Virologic Suppression In PRO 140 Monotherapy Study 9/21/2015 8:10:23 AM
CytoDyn Release: First Self-Injectable HIV Antibody: 98% Success Rate In Phase 2b Clinical Trial, Could Be Commercial 8/18/2015 10:57:08 AM
CytoDyn Initiates First Clinical Site For Phase III Trial Of PRO 140 8/6/2015 7:32:04 AM
CytoDyn Completes Qualification Of PRO 140 Material For Phase III 7/29/2015 7:52:23 AM
CytoDyn Release: Evidence Of HIV Suppression With PRO 140 Monotherapy Reaching Nearly 11 Months 7/15/2015 7:15:51 AM
CytoDyn To Expand Clinical Applications For PRO 140 Beyond Therapy For HIV 6/24/2015 11:22:31 AM
CytoDyn Cleared By FDA To Start Phase III Of First Injectable Antibody For HIV 6/9/2015 7:25:32 AM
CytoDyn Submits Phase 3 Protocol To FDA After Agreement On Protocol Synopsis 5/4/2015 2:43:46 PM
CytoDyn Concludes Phase 2b Study With 98% Success With 4 Weeks Of Monotherapy - Many HIV Patients In Extension Study With Some Approaching 6 Months 2/3/2015 7:12:06 AM
CytoDyn Information Now Available Through S&P Capital IQ Corporation Records Program 11/25/2014 9:36:38 AM